id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2002-P-0166-0002,FDA,FDA-2002-P-0166,FDA/CDER to AAC Consulting Group,Other,PAV-Petition Approval,2002-12-06T05:00:00Z,2002,12,,,2008-04-12T01:26:53Z,,0,0,09000064804945df
FDA-2002-P-0166-0001,FDA,FDA-2002-P-0166,FDA/DDM to AAC Consulting Group,Other,ACK-Acknowledgement Letter,2002-05-30T04:00:00Z,2002,5,,,2008-04-12T01:26:53Z,,0,0,09000064804945ae